1. Adjuvant docetaxel for high-risk, node-negative breast cancer
- Author
-
Martin, Miguel, Segui, Miguel A., Anton, Antonio, Ruiz, Amparo, Ramos, Manuel, Adrover, Encarna, Aranda, Ignacio, Rodriguez-Lescure, Alvaro, Grobe, Regina, Calvo, Lourdes, Barnadas, Agusti, Isla, Dolores, del Prado, Purification Martinez, Borrego, Manuel Ruiz, Zaluski, Jerzy, Arcusa, Angels, Munoz, Montserrat, Vega, Jose M. Lopez, Mel, Jose R., Munarriz, Blanca, Llorca, Cristina, Jara, Carlos, Alba, Emilio, Florian, Jesus, Junfang Li, Garcia-Asenjo, Jose A. Lopez, Saez, Amparo, Rios, Maria Jose, Almenar, Sergio, Peiro, Gloria, and Lluch, Ana
- Subjects
Breast cancer -- Risk factors ,Breast cancer -- Drug therapy ,Docetaxel -- Health aspects ,Doxorubicin -- Health aspects ,Cyclophosphamide -- Health aspects ,Fluorouracil -- Health aspects ,Cancer -- Adjuvant treatment ,Cancer -- Patient outcomes - Abstract
A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is shown to be superior to a regimen of fluorouracil, doxorubicin and cyclophosphamide (FAC) when they are used as adjuvant therapy in women with node-positive breast cancer. The studies have shown that when compared with adjuvant FAC, adjuvant TAC has improved the rate of disease-free survival among women with high-risk, node-negative breast cancer.
- Published
- 2010